DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Hagenbeck C, Melcher CA, Janni JW et al.
DETECT III: a multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC).
J Clin Oncol 2012;
30 (Suppl.) Abstr. TPS1146
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.